$33.6 Million is the total value of UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO's 24 reported holdings in Q2 2017. The portfolio turnover from Q1 2017 to Q2 2017 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
WPZ | WILLIAMS PARTNERS LPlp - public equity | $6,928,000 | -1.8% | 172,732 | 0.0% | 20.60% | +11.8% | |
TXN | TEXAS INSTRUMENTS INC | $2,462,000 | -4.5% | 32,000 | 0.0% | 7.32% | +8.7% | |
AGLE | AEGLEA BIOTHERAPEUTICS INC | $2,021,000 | -48.3% | 524,929 | 0.0% | 6.01% | -41.2% | |
BPTH | BIO-PATH HOLDINGS INC | $1,456,000 | -53.5% | 3,830,882 | 0.0% | 4.33% | -47.1% | |
MGEN | MIRAGEN THERAPEUTICS INC | $1,364,000 | +4.0% | 105,465 | 0.0% | 4.06% | +18.4% | |
GMOLQ | GENERAL MOLY INC | $1,080,000 | -26.1% | 2,922,831 | 0.0% | 3.21% | -15.9% | |
LXRX | LEXICON PHARMACEUTICALS INC | $587,000 | +14.6% | 35,714 | 0.0% | 1.74% | +30.5% | |
JNCE | JOUNCE THERAPEUTICS INC | $428,000 | -36.1% | 30,488 | 0.0% | 1.27% | -27.3% | |
PK | PARK HOTELS & RESORTS INCfunds, real estate investment trusts, domestic | $258,000 | +4.9% | 9,587 | 0.0% | 0.77% | +19.5% | |
POR | PORTLAND GENERAL ELECTRIC CO | $5,000 | 0.0% | 118 | 0.0% | 0.02% | +15.4% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-08-03
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
TEXAS INSTRUMENTS INC | 41 | Q3 2023 | 31.2% |
PORTLAND GENERAL ELECTRIC CO | 38 | Q3 2023 | 0.0% |
LEXICON PHARMACEUTICALS INC | 33 | Q3 2023 | 1.7% |
AEGLEA BIOTHERAPEUTICS INC | 27 | Q2 2023 | 11.0% |
APOLLO ENDOSURGERY INC | 24 | Q1 2023 | 5.6% |
PLX PHARMA INC | 23 | Q1 2023 | 1.7% |
VANGUARD MSCI EMERGING MKTS | 22 | Q2 2019 | 10.3% |
VANGUARD ENERGY ETF | 22 | Q2 2019 | 8.7% |
VANGUARD S&P 500 ETF | 21 | Q3 2023 | 11.8% |
VANGUARD MSCI EAFE ETF | 20 | Q2 2019 | 13.1% |
View UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Taysha Gene Therapies, Inc. | September 24, 2021 | 1,156,255 | 3.0% |
ZIOPHARM ONCOLOGY INC | February 12, 2016 | 9 | 0.0% |
View UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
4 | 2024-05-01 |
3 | 2024-04-30 |
13F-HR | 2024-04-30 |
144 | 2024-04-29 |
SC 13G | 2024-03-05 |
13F-HR | 2024-02-28 |
SC 13G | 2024-02-14 |
13F-HR | 2023-11-09 |
13F-HR | 2023-08-04 |
3 | 2023-06-02 |
View UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.